secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harvard Apparatus Regenerative Technology, Inc. (HRGN)
CIK:        0001563665
Form:       8-K
Filed at:   2022-05-16T23:59:59+00:00
Accession:  0001558370-22-008977
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biostage Q1 net loss widens to $2.2M; settles lawsuit, raises $5.1M placement
-----------------------------------------------------------------------------

- Q1 net loss of $2.2M ($0.20 per share) vs $0.9M loss ($0.09) in Q1 2021; G&A up $1.4M on legal costs.
- Raised $5.1M via private placement on May 12, 2022 to fund clinical development of BEI.
- Settled wrongful death lawsuit on April 27, 2022; total estimated costs $6.0M, $5.5M unpaid; HBIO to pay $4.0M.
- Cash on hand $0.7M at March 31, 2022; after placement, cash expected to fund operations through Q1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563665/000155837022008977/0001558370-22-008977-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563665/000155837022008977/tmb-20220516x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-008977

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer